IL236041A - 1- [6 - [[5- (2-Fluoropropyl) -3-methyl-triazole-4-yl] methoxy] -3-pyridyl] imidazole-4-carbonitrile or its common pharmaceutical salt and such compound for use in the treatment of diseases - Google Patents
1- [6 - [[5- (2-Fluoropropyl) -3-methyl-triazole-4-yl] methoxy] -3-pyridyl] imidazole-4-carbonitrile or its common pharmaceutical salt and such compound for use in the treatment of diseasesInfo
- Publication number
- IL236041A IL236041A IL236041A IL23604114A IL236041A IL 236041 A IL236041 A IL 236041A IL 236041 A IL236041 A IL 236041A IL 23604114 A IL23604114 A IL 23604114A IL 236041 A IL236041 A IL 236041A
- Authority
- IL
- Israel
- Prior art keywords
- carbonitrile
- triazol
- fluorophenyl
- pyridyl
- imidazole
- Prior art date
Links
- RXSRUWRCDDEWSN-UHFFFAOYSA-N 1-[6-[[5-(2-fluorophenyl)-3-methyltriazol-4-yl]methoxy]pyridin-3-yl]imidazole-4-carbonitrile Chemical compound CN1N=NC(C=2C(=CC=CC=2)F)=C1COC(N=C1)=CC=C1N1C=NC(C#N)=C1 RXSRUWRCDDEWSN-UHFFFAOYSA-N 0.000 title 1
- 150000001875 compounds Chemical class 0.000 title 1
- 201000010099 disease Diseases 0.000 title 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title 1
- 150000003839 salts Chemical class 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Epidemiology (AREA)
- Physical Education & Sports Medicine (AREA)
- Psychology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Addiction (AREA)
- Obesity (AREA)
- Child & Adolescent Psychology (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Hospice & Palliative Care (AREA)
- Anesthesiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261664287P | 2012-06-26 | 2012-06-26 | |
| DKPA201270368 | 2012-06-26 | ||
| PCT/EP2013/063193 WO2014001281A1 (en) | 2012-06-26 | 2013-06-25 | A phenyl triazole derivative and its use for modulating the gabaa receptor complex |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| IL236041A0 IL236041A0 (en) | 2015-02-01 |
| IL236041A true IL236041A (en) | 2016-09-29 |
Family
ID=49782299
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL236041A IL236041A (en) | 2012-06-26 | 2014-12-03 | 1- [6 - [[5- (2-Fluoropropyl) -3-methyl-triazole-4-yl] methoxy] -3-pyridyl] imidazole-4-carbonitrile or its common pharmaceutical salt and such compound for use in the treatment of diseases |
Country Status (10)
| Country | Link |
|---|---|
| US (2) | US9206160B2 (enExample) |
| EP (1) | EP2877463B1 (enExample) |
| JP (1) | JP6224097B2 (enExample) |
| KR (1) | KR20150033678A (enExample) |
| CN (1) | CN104411699B (enExample) |
| AU (1) | AU2013283487C1 (enExample) |
| CA (1) | CA2876778A1 (enExample) |
| IL (1) | IL236041A (enExample) |
| MX (1) | MX357504B (enExample) |
| WO (1) | WO2014001281A1 (enExample) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10472324B2 (en) | 2014-03-18 | 2019-11-12 | Algiax Pharmaceuticals Gmbh | 2-cyano-3-cyclopropyl-3-hydroxy-N-aryl-thioacrylamide derivatives |
| BR102019014802A2 (pt) | 2018-07-20 | 2020-02-04 | Boehringer Ingelheim Int | difluorometil-fenil triazóis |
| HU231223B1 (hu) | 2018-09-28 | 2022-01-28 | Richter Gedeon Nyrt. | GABAA A5 receptor modulátor hatású biciklusos vegyületek |
| EP3858965B1 (en) * | 2020-01-28 | 2022-05-11 | The Procter & Gamble Company | Cleaning product |
| TWI901650B (zh) * | 2020-03-26 | 2025-10-21 | 匈牙利商羅特格登公司 | 啶及吡啶并〔３，４－ｃ〕嗒衍生物 |
| EP4126858B1 (en) | 2020-03-26 | 2026-03-18 | Richter Gedeon Nyrt. | Dihydro-2-pyrrolo[3,4-c]pyridine derivatives as gabaa a5 receptor modulators |
| CN116888115B (zh) * | 2020-08-05 | 2026-03-20 | 萨尼奥纳有限责任公司 | 二氟甲基-吡啶-2-基三唑 |
| CA3228655A1 (en) * | 2021-08-12 | 2023-02-16 | Shanghai SIMR Biotechnology Co., Ltd | Substituted triazole derivative, preparation method therefor, pharmaceutical composition thereof, and use thereof |
| WO2024023268A1 (en) | 2022-07-29 | 2024-02-01 | F. Hoffmann-La Roche Ag | Characterisation of neurological dysfunction |
Family Cites Families (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2314401A1 (en) * | 1997-12-22 | 1999-07-01 | Du Pont Pharmaceuticals Company | Nitrogen containing heteroaromatics with ortho-substituted p1's as factor xa inhibitors |
| CA2623043A1 (en) | 2005-09-19 | 2007-04-12 | F. Hoffman-La Roche Ag | Isoxazolo derivatives as gaba a alpha5 inverse agonists |
| BRPI0617306A2 (pt) | 2005-10-11 | 2011-07-19 | Hoffmann La Roche | derivados de isoxazol |
| BRPI0618383A2 (pt) | 2005-11-09 | 2011-08-30 | Hoffmann La Roche | derivados de 3-aril-isoxazol-4-carbonil-benzofurano |
| BRPI0620146A2 (pt) | 2005-12-23 | 2011-11-01 | Hoffmann La Roche | derivados de aril-isoxazolo-4-il-oxadiazol, processo para a preparação dos referidos derivados, medicamento que os contém e usos de um desses derivados |
| JP4864982B2 (ja) | 2005-12-27 | 2012-02-01 | エフ．ホフマン−ラ ロシュ アーゲー | アリール−イソオキサゾール−４−イル−イミダゾ［１，５−ａ］ピリジン誘導体 |
| KR101121372B1 (ko) | 2005-12-27 | 2012-04-12 | 에프. 호프만-라 로슈 아게 | 아릴-이속사졸-4-일-이미다졸 유도체 |
| CA2651857A1 (en) | 2006-05-31 | 2007-12-06 | F. Hoffmann-La Roche Ag | Aryl-4-ethynyl-isoxazole derivatives |
| EP1894924A1 (en) | 2006-08-29 | 2008-03-05 | Phenex Pharmaceuticals AG | Heterocyclic FXR binding compounds |
| EP1894928A1 (en) | 2006-08-29 | 2008-03-05 | PheneX Pharmaceuticals AG | Heterocyclic fxr binding compounds |
| BRPI0814718A2 (pt) | 2007-06-22 | 2015-02-24 | Hoffmann La Roche | Derivados de isoxazol-imidazol |
| CA2706990C (en) | 2007-12-04 | 2016-05-10 | F. Hoffmann-La Roche Ag | Isoxazolo-pyrazine derivatives |
| EP2227467B1 (en) | 2007-12-04 | 2014-12-31 | F. Hoffmann-La Roche AG | Isoxazolo-pyridine derivatives |
| US7943619B2 (en) | 2007-12-04 | 2011-05-17 | Hoffmann-La Roche Inc. | Isoxazolo-pyridazine derivatives |
| EP2128158A1 (en) | 2008-05-26 | 2009-12-02 | Phenex Pharmaceuticals AG | Heterocyclic cyclopropyl-substituted FXR binding compounds |
| US8389550B2 (en) | 2009-02-25 | 2013-03-05 | Hoffmann-La Roche Inc. | Isoxazoles / O-pyridines with ethyl and ethenyl linker |
| US8222246B2 (en) | 2009-04-02 | 2012-07-17 | Hoffmann-La Roche Inc. | Substituted isoxazoles |
| US20100280019A1 (en) | 2009-04-30 | 2010-11-04 | Roland Jakob-Roetne | Isoxazoles |
| ES2467701T3 (es) | 2009-05-05 | 2014-06-12 | F. Hoffmann-La Roche Ag | Derivados de isoxazol-piridazina |
| AU2010244552A1 (en) | 2009-05-05 | 2011-09-29 | F. Hoffmann-La Roche Ag | Isoxazole-pyrazole derivatives |
| SG175869A1 (en) | 2009-05-05 | 2011-12-29 | Hoffmann La Roche | Isoxazole-thiazole derivatives as gaba a receptor inverse agonists for use in the treatment of cognitive disorders |
| WO2010127976A1 (en) | 2009-05-05 | 2010-11-11 | F. Hoffmann-La Roche Ag | Isoxazole-pyridine derivatives |
| AU2010244555A1 (en) | 2009-05-07 | 2011-11-03 | F. Hoffmann-La Roche Ag | Isoxazole-pyridine derivatives as GABA modulators |
| EP2289883A1 (en) | 2009-08-19 | 2011-03-02 | Phenex Pharmaceuticals AG | Novel FXR (NR1H4) binding and activity modulating compounds |
| NZ608592A (en) | 2010-11-05 | 2015-08-28 | Hoffmann La Roche | Use of active pharmaceutical compounds for the treatment of central nervous system conditions |
| US8742097B2 (en) * | 2010-11-09 | 2014-06-03 | Hoffmann-La Roche Inc. | Triazole compounds I |
| US8466181B2 (en) * | 2010-12-10 | 2013-06-18 | Hoffmann-La Roche Inc. | 1,2,3-triazole-imidazole compounds |
-
2013
- 2013-06-25 CA CA2876778A patent/CA2876778A1/en not_active Abandoned
- 2013-06-25 KR KR20157001888A patent/KR20150033678A/ko not_active Ceased
- 2013-06-25 JP JP2015519034A patent/JP6224097B2/ja not_active Expired - Fee Related
- 2013-06-25 EP EP13732127.9A patent/EP2877463B1/en not_active Not-in-force
- 2013-06-25 MX MX2014014871A patent/MX357504B/es active IP Right Grant
- 2013-06-25 US US14/411,331 patent/US9206160B2/en not_active Expired - Fee Related
- 2013-06-25 AU AU2013283487A patent/AU2013283487C1/en not_active Ceased
- 2013-06-25 WO PCT/EP2013/063193 patent/WO2014001281A1/en not_active Ceased
- 2013-06-25 CN CN201380033706.1A patent/CN104411699B/zh not_active Expired - Fee Related
-
2014
- 2014-12-03 IL IL236041A patent/IL236041A/en not_active IP Right Cessation
-
2015
- 2015-11-16 US US14/942,705 patent/US9931329B2/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| US9931329B2 (en) | 2018-04-03 |
| AU2013283487A1 (en) | 2015-01-22 |
| IL236041A0 (en) | 2015-02-01 |
| US20160067234A1 (en) | 2016-03-10 |
| JP6224097B2 (ja) | 2017-11-01 |
| MX357504B (es) | 2018-07-12 |
| MX2014014871A (es) | 2015-06-17 |
| EP2877463A1 (en) | 2015-06-03 |
| AU2013283487B2 (en) | 2017-05-25 |
| CN104411699A (zh) | 2015-03-11 |
| CN104411699B (zh) | 2017-06-13 |
| WO2014001281A1 (en) | 2014-01-03 |
| KR20150033678A (ko) | 2015-04-01 |
| JP2015521642A (ja) | 2015-07-30 |
| CA2876778A1 (en) | 2014-01-03 |
| US20150152085A1 (en) | 2015-06-04 |
| AU2013283487C1 (en) | 2018-01-18 |
| EP2877463B1 (en) | 2018-11-07 |
| US9206160B2 (en) | 2015-12-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL287313B (en) | Bipyrazole derivatives or a medicinal salt are acceptable for use in the treatment of diseases associated with jak activity | |
| IL232251B (en) | Pharmaceutical combination for use in the treatment of type 2 diabetes patients | |
| HK1216176A1 (zh) | 用於治疗增殖性和自身免疫疾病的非对称吡咯并苯并二氮杂卓二聚物 | |
| HK1211475A1 (en) | Combination therapy | |
| IL217901B (en) | Use of laquinimod or a laquinimod salt in the manufacture of a drug for the treatment of bdnf-related diseases | |
| IL223783B (en) | Compound 1-converted indole for use in the treatment of a disease or condition, a pharmaceutical preparation containing the compound and use of the compound to prepare a medicine | |
| IL228669B (en) | Combinations that include brexpiprazole or its salt and a second drug for use in the treatment of a central nervous system disorder | |
| IL210589A (en) | C2386RV Protein Tuberculosis Kvfb Protein Use for the Treatment or Prevention of TB | |
| IL231591A0 (en) | Converted benzylindazoles for use as bub1 kinase inhibitors in the treatment of hyperproliferative diseases | |
| IL231536A (en) | Indazole-3-carboxamides, pharmaceuticals containing them and their use in the treatment of diseases | |
| PT2822555T (pt) | Inibição da cinase 1 associada a adaptador para o tratamento da dor | |
| IL232325A0 (en) | 18-methyl-7,6-methylene-3-oxo-17-paragan-4-en-21, 17b-carbolactones, pharmaceutical preparations containing these compounds and their use for the treatment of endometrial disease | |
| IL239278B (en) | Compound containing pyridine or pyrimidine and non-aryl heterocyclic amine, drug, and compounds for use in the prevention or treatment of epilepsy or neurodegenerative disease | |
| IL237649B (en) | Polymer meters drug for use in the prevention, diagnosis and/or treatment of diseases of the joint | |
| ZA201401678B (en) | Novel distributed 3,4-diamino-cyclobutene-1,2-dione compounds for use in the treatment of chemokine-mediated diseases | |
| PL2739615T3 (pl) | Fenylo-3-aza-bicyklo[3.1.0]heks-3-ylo-metanony i ich zastosowanie jako leki | |
| IL218674A (en) | Compounds that inhibit lrrk2 kinase activity, pharmacological preparations containing them, and their use in the preparation of Parkinson's disease drugs | |
| IL223543A (en) | Pharmaceutical preparation containing 1– (4– (4– (4,3-dichloro-2 – fluorophenylamino) –7 – methoxyquinazoline – 6 – Iloxy) piperidine – 1 – il) Prof. 2 – an – 1 – on or a common pharmaceutical salt His and an acidic addition | |
| PL2726470T3 (pl) | Pochodne 1,2,4-tiadiazol-5-ilo piperazyny przydatne w leczeniu chorób neurodegeneracyjnych | |
| IL234862A0 (en) | Vascular formulations and their use for the treatment of pain or reduced mobility of a joint | |
| IL260078B (en) | Therapy used to treat Gaucher disease | |
| ZA201402477B (en) | Compounds for use in the treatment of alzheimer's disease | |
| EP3065548A4 (en) | Fibrosis inhibiting compounds and methods of use thereof in the prevention or treatment of fibrosing diseases | |
| IL238071B (en) | Pharmaceutical composition of 1-adamantylethyloxy-3-morpholino-2-propanol or pharmaceutically acceptable salts thereof for the treatment of cardiovascular disease | |
| WO2011156900A3 (en) | Compounds, compositions and methods for treatment of multiple sclerosis |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FF | Patent granted | ||
| KB | Patent renewed | ||
| MM9K | Patent not in force due to non-payment of renewal fees |